US 10,517,875 B2Granted

Targeting DNA-PKcs and B7-H1 to treat cancer

AssigneeMayo Foundation for Medical Engineering and Research

InventorHaidong Dong

Life of this patent

Estimating the term…

Materials and methods for treating potentially chemoresistant tumors (e.g., using DNA-PKcs inhibitors and anti-B7-H1 antibodies) are provided herein.

Dependent claims

A method for treating a cancer patient, comprising:

(a) administering, to a cancer patient to be treated with a chemotherapeutic agent that causes DNA damage, an amount of a molecule targeted to DNA-PKcs sufficient to reduce the interaction of DNA-PKcs with B7-H1, wherein the molecule targeted to DNA-PKcs comprises NU7026, NU7441, IC86621, IC87102, IC87361, OK-1035, SU11752, vanillin, or IC486241;
and
(b) administering the chemotherapeutic agent to the patient.

Dependencies are inferred from the claim text.

A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4745
Ortho- or peri-condensed with heterocyclic ring systems: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…
A61K 33/243
Heavy metals; Compounds thereof: platinum; Compounds thereof

From the US filing history. Foreign family members aren’t listed.

Loading patent…